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With the ever-mounting evidence for a profound and direct effect of SGLT2 inhibitors (SGLT2i’s) 18 
on the heart, understanding their mechanism of action becomes increasingly important. So, we 19 
are pleased that our paper1 published in this edition of Cardiovascular Research, has generated 20 
a lively debate.2, 3 In our work, we use a variety of methods to show that, at least in our hands, 21 
empagliflozin (EMPA) from two independent suppliers, as well as two other chemically-related 22 
SGLT2i's, are not potent inhibitors of the cardiac Na+/H+ exchanger-1 (NHE1) and, related to 23 
this, have no effect on intracellular Na+ concentration ([Na+]i) in the healthy heart. This is 24 
contrary to several previous reports (see references 1-4 in Zuurbier et al.2). 25 
 26 
Our findings are in contrast with Zuurbier and colleagues in Amsterdam, who have responded 27 
to our work with a short letter in this issue of Cardiovascular Research.2 Their letter contains 28 
some misunderstandings and errors that warrant a response from us. However, before briefly 29 
responding to this letter, it is important to say that our labs in London and Oxford, and those of 30 
Zuurbier and colleagues in Amsterdam, have been in useful and regular correspondence over 31 
the last 6 months to try to understand the reasons for our contrasting results. We also add that 32 
we have the highest regard for the Amsterdam group, and the quality of their science, as well 33 
as a long-standing personal friendship between our groups. So, in the spirit of constructively 34 
trying to understand what underlies these apparently contrasting findings, we make the 35 
following observations: 36 
 37 
1. EMPA and intracellular Na concentration: In their letter, Zuurbier et al claim that, when 38 
'calibrated', our SBFI data support the notion that EMPA lowers the intracellular Na 39 
concentration in isolated cells. They arrive at this conclusion by transcribing and re-analysing 40 
our SBFI ratios, read from our original figure (Figure 3A in Chung et al1). While a post-hoc 41 
application of an arbitrary calibration curve is unlikely to be reliable, the Amsterdam group 42 
were kind enough to share their spreadsheet and analysis with us. Unfortunately, our data 43 
has been mis-transcribed and includes some outliers that were not present in our original 44 
data set as well as other transcription errors. Never the less, using our real observed values 45 
and the calibration equation provided in Zuurbier et al, a retrospective calibration of our 46 
data does not alter our original assertion that EMPA (1 or 10 µM) has no effect on 47 
intracellular Na+ (see Figure 1 - inset table). 48 
 49 
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2. Type I vs Type II errors: The Zuurbier et al letter claims that they have published extensively 50 
showing evidence for SGLT2i’s inhibiting NHE1 activity in rabbits and mice. However, these 51 
studies, taken individually, are based on a relatively small number of observations: the 52 
primary observation of NHE1 inhibition in Baartscheer et al (2017) for example, is made in 53 
5-6 cells from 4 rabbits (Figure 2c), in Uthman et al (2018) in 8 cells from 4 mice (Figure 1) 54 
and Uthman et al (2019) 8 cells from 5 mice (Figure 5) (see reference 1-3 in Zuurbier et al2).  55 
In the recent letter by Zuurbier et al, the primary observation (Figure 1A) is based on 3 cells 56 
from 3 rabbits.2 The [Na+]-lowering effect is based on similarly small sample sizes.  57 
 58 
 As David Eisner points out in a separate recent review, the use of the number of cells as the 59 
statistical sample size is valid only when comparing 'before' and 'after' drug interventions, 60 
as is the case for our cellular [Na+] responses (Figure 3 in Chung et al1).4 The use of 61 
hierarchical statistical analysis can also limit bias due to inter-animal variability. However, 62 
the likelihood of a Type I error (i.e. false positive) increases as sample size declines, when 63 
data are clustered, or when not implementing repeated measures or hierarchical analyses.4  64 
 65 
 Our inferences, on the other hand, may be prone to a Type II error (false negative). We have 66 
therefore reanalysed the intracellular [Na+] data using hierarchical (nested) analysis (to avoid 67 
clustering bias) as well as paired t-tests (more likely to detect a systematic small difference). 68 
However, these analyses also fail to detect any statistically significant reduction of 69 
intracellular Na by EMPA in healthy myocytes (Figure 1). Our single-cell Na studies are based 70 
on 24-33 cells in each experimental group and are 'paired'. These observations are supported 71 
by 'unpaired' intracellular Na measurements made using 23Na NMR spectroscopy in isolated 72 
rat, mouse (n=6/group) and guinea pig hearts beating at physiological rates where again no 73 
changes in Na are observed. Our measurements of NHE1 activity are 'unpaired' as they were 74 
made in separate cells as myocytes do not usually tolerate two consecutive NH4 prepulses. 75 
However, hierarchical cluster analysis based on 24-39 cells from at least 3 rats (8 cells from 76 
2 rats for cariporide) using the summary variable of NHE1 flux at pH 6.9, shows no effect of 77 
EMPA (and a significant effect of cariporide) (Figure 1).    78 
 79 
3. Specificity and sensitivity of the NHE1 assay: The Zuurbier et al letter suggests that our 80 
inability to detect an inhibition of NHE1 activity using our set-up is compromised by the 81 
“non-specificity” and “low-sensitivity” of our NHE1 assay. We respond to these 82 
unsubstantiated claims by arguing that the method used in Amsterdam is, in fact, more 83 
prone to be affected by non-specificity and low-sensitivity. 84 
 85 
An NHE1-specific assay that is based on measurements of intracellular pH (pHi) must ensure 86 
that the only transporter responsible for producing a H+-equivalent flux is NHE1. We do this 87 
by eliminating any contribution from HCO3--dependent transporters (by buffering our 88 
solution with HEPES only). In contrast, the ‘Amsterdam’ protocol adds bicarbonate to their 89 
solutions, which inadvertently activates transporters in addition to NHE1. Thus, non-90 
specificity is a greater concern with the Amsterdam approach. Zuurbier et al point out that 91 
our recordings show a partial recovery of pHi in the presence of the NHE1 inhibitor 92 
cariporide, and conclude that our system thus has a non-NHE1 component. This reasoning 93 
is, however, flawed because it ignores the fact that the dose of drug used - 10 µM - is not 94 
a concentration at which cariporide is a full inhibitor. Previously, it was determined by 95 
Ch’en et al (2008) that 30 µM is required to block NHE1 in rat myocytes.5 Nonetheless, we 96 
observe a 90% inhibition of flux in the presence of 10 µM cariporide. The pHi recovery is 97 
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other studies, we have consistently used 30 µM cariporide to block NHE1, but in this 99 
instance, we opted for a concentration to match that of EMPA. In our NHE1 assay using 100 
HCT116 cells (Chung et al Supplement Figure 4S), we show a 97% inhibition of NHE1 flux 101 
with 30 µM cariporide.1 102 
 103 
 With regard to sensitivity, an NHE1 assay must (i) ensure that the transporter’s activity 104 
under control conditions is sufficiently large to detect even a small inhibitory effect of 105 
candidate-drugs, (ii) that the actions of drugs are expressed in terms of flux, i.e the most 106 
accurate functional measure of NHE1 activity, and (iii) that fluxes are compared at matching 107 
levels of transport substrate (i.e. pHi). With respect to the first point, we were perplexed 108 
to read that our assay was deemed to be ‘not sensitive enough’ because our NHE1 activity 109 
is too high. Our measurements peaked at 20 mM/min at low pH; as expected for rats and 110 
consistent with the literature.6, 7 Yamamoto et al (2005) have previously showed that NHE1 111 
flux in rabbit myocytes is over four times slower than in rat myocytes.8 Rabbit myocytes 112 
are thus a less sensitive system to study NHE1 inhibitors. The sensitivity of NHE1 113 
measurements in rabbits (and those in mice) by the Amsterdam protocol was further 114 
compromised by performing recordings at the unphysiological extracellular pH of 7.2-7.3, 115 
an inhibitory influence. As shown by Vaughan-Jones and Wu (1990), the relationship 116 
between extracellular pH and NHE activity is particularly steep between pH 7.0 and 7.5, 117 
thus the use of mildly acidotic conditions will further reduce NHE activity and hence 118 
compromise its ability to resolve inhibition.9 At the lower NHE1 activity in rabbits, it is not 119 
surprising that even a low dose of cariporide results in an apparent block of transport; in 120 
reality, there is a small residual activity that is simply not big enough to resolve. We argue 121 
that to measure the inhibitory effect of a drug, transmembrane H+-equivalent flux should 122 
be calculated correctly, i.e. from the product of pHi change and buffering capacity and 123 
plotted against the corresponding pHi at which it was calculated to generate a pH-flux 124 
curve, as has been the standard established in our lab for over 2 decades. Additional 125 
transformations such as normalizations performed in the Zuurbier letter and comparing 126 
these slopes without taking into account the level of substrate (i.e. pHi) are problematic. 127 
NHE1 is steeply sensitive to pHi, therefore the effects of drugs must be compared at 128 
precisely matching levels of pHi.  129 
 130 
4. Isolated heart studies: Both groups appear to be in agreement that EMPA has no effect on 131 
contractility in isolated hearts. The lack of a negative inotropic effect of SGLT2i’s has been 132 
widely reported - not only by our respective groups but also in many other studies in a wide 133 
range of models. The Uthman et al and Baartcheer et al studies report a fall in Na of 20-134 
25%. Given the steep relationship between [Na+]i and contractility (for example see 135 
Eisner),10 a reduction in [Na+]i of this magnitude would be expected to elicit a negative 136 
inotropic response which is not observed. The lack of changes in inotropy reported in these 137 
studies is therefore surprising and suggests there are some, as yet undefined, confounding 138 
factors. Alternatively, the lack of a negative inotropic effect with this degree of [Na+]i 139 
reduction supports our contention that intracellular [Na+] does not fall acutely in intact 140 
healthy hearts in response to SGLTi’s.   141 
 142 
5. SGLT2i’s in pathology: While Na may not fall in healthy hearts, we agree that the beneficial 143 
effects of SGLT2i's may be particularly apparent under pathological conditions. Indeed, 144 
with regard to Na fluxes, a recent study by Philippaert et al has reported that EMPA blocks 145 
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 In this regard it is also interesting that Zuurbier et al cite the excellent study of Cappetta et 148 
al (see reference 5 in Zuurbier et al.2). In this study, Cappetta and colleagues report that 149 
dapagliflozin inhibits NHE in HUVECs. Studies originating from the Amsterdam group have 150 
also reported that SGLT2i's can inhibit ROS production and improve NO bioavailability in 151 
HUVECs.12 So, while SGLT2i's may inhibit NHE in endothelial cells, it is far from certain that 152 
this is a direct effect - particularly as high concentrations of NO have been shown to inhibit 153 
NHE1.7  Perhaps of more relevance to the present debate is Cappetta et al's observation 154 
that in cardiomyocytes, dapagliflozin had no acute effect either on systolic or diastolic Ca 155 
or on diastolic intracellular Na. They concluded that "These observations suggest that the 156 
beneficial effects on Ca and Na homeostasis that we observed after 6 weeks of dapagliflozin 157 
treatment in vivo were not caused by a direct acute modification of [Na] and Ca ion fluxes 158 
and concentrations by the drug. Therefore, in our experimental setting, dapagliflozin did 159 
not directly target cardiomyocyte ion transporters or channels that would otherwise 160 
determine instantaneous changes in intracellular Ca and Na." This therefore seems an odd 161 
paper to cite in support of their argument.  162 
 163 
6. Conclusions: At present, we remain puzzled as to why we can find no evidence for SGLTi’s 164 
inhibiting NHE1 or lowering [Na+]i in the healthy myocardium, as reported by the 165 
Amsterdam group and by Trum et al (see reference 4 in Zuurbier et al.2) Zuurbier et al in 166 
their recent letter have explored some differences, and we have discussed others. 167 
However, while there are clear protocol differences between our studies, we do not believe 168 
that any of them are likely to be sufficient to explain such profoundly different results. 169 
Indeed, this is the conclusion also reached by Zuurbier et al. The mechanisms by which 170 
SGLT2i’s elicit their important beneficial effects in the heart remain unresolved and 171 
therefore fertile ground for further research. We would therefore welcome suggestions 172 
from the wider community and, when we hopefully emerge from this COVID pandemic, our 173 
labs will get together in Oxford, London and Amsterdam to try to unravel this conundrum. 174 
 175 
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Figure Legend: 223 
 224 
Figure 1: Intracellular Na measurements and NHE1 flux at pH 6.9 estimated from our original 225 
data (Chung et al). Left Panel: Using the calibration described by Zuurbier et al the SBFI 226 
ratiometric values were converted into intracellular Na ([Na+]i). Right Panel: NHE1 flux was 227 
measured at pH 6.9. In both panels, each data point represents a single observation and these 228 
are colour-coded to identify individual cell isolations. The mean values are shown in the inset 229 
tables.  Using hierarchical analysis, the intraclass correlation coefficient of the [Na+]i and NHE1 230 
flux data were 32% and 3.2% respectively - demonstrating the need to use hierarchical 231 
statistical test on these type of data.  When tested with hierarchical (nested) t-tests, EMPA has 232 
no effect on [Na+]i or NHE1 flux as previously reported. Cardiporide very significantly reduced 233 
NHE1 flux whether tested by unpaired t-test or by hierarchical analysis. A paired t-test (but not 234 
nested hiererchical analysis) detects a small but significant (likely erroneous) reduction in [Na+]i 235 
by cariporide. ns = not significant. Note: we have undertaken the retrospective Na calibration 236 
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